STOCK TITAN

Zentek earns C$17.2M after Albany impairment reversal

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Zentek Ltd. (ZTEKF) reported $13.6 million in cash and $11.3 million in working capital at September 30, 2026, compared with $1.3 million in cash and a $1.3 million working-capital deficit at March 31, 2026. The May 2026 financing provided approximately $16 million in net proceeds. Total assets were $49.4 million, versus $15.1 million at March 31, mainly reflecting the financing and reversal of the Albany Graphite Project impairment. All amounts are in Canadian dollars.

Quarterly net income was $17.2 million, including a non-cash $19.7 million impairment reversal; excluding that item, Zentek reported a $2.5 million loss, about the same as a year earlier. The reversal left Albany's carrying amount at approximately $28.8 million. For the six months ended September 30, 2026, cash used in operating activities was $3.6 million, versus $2.4 million a year earlier. Since the financing closed, Zentek spent $1.2 million on Albany development and de-risking, including completing its preliminary economic assessment. ZenGUARD filters are selling in Canada and the United States.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointWorking capital reached $11.3 million, from a $1.3 million deficit.

Negative

  • Moderate pointSix-month operating cash use rose to $3.6 million from $2.4 million.

Filing Explained

In its interim results, Zentek estimated Albany’s fair value less costs of disposal at $45.5 million to $58.5 million, but capped the $19.7 million impairment reversal at the amount the asset would have carried without the old impairment, leaving a reported carrying amount of $28.8 million.

Cash $13.6 million CAD; as of September 30, 2026
Working capital $11.3 million CAD; as of September 30, 2026, compared with a $1.3 million deficit at March 31, 2026
May financing net proceeds Approximately $16 million CAD; May 2026 financing
Total assets $49.4 million CAD; as of September 30, 2026, compared with $15.1 million at March 31, 2026
Albany impairment reversal Approximately $19.7 million CAD; non-cash reversal recognized for the three and six months ended September 30, 2026
Quarterly net income $17.2 million CAD; three months ended September 30, 2026, including the impairment reversal
Loss excluding impairment reversal $2.5 million loss CAD; three months ended September 30, 2026; about the same as a year earlier
Cash used in operating activities $3.6 million CAD; six months ended September 30, 2026, compared with $2.4 million a year earlier
fair value less costs of disposal financial
"fair value less costs of disposal ("FVLCD")"
impairment reversal financial
"the reversal of a previously recognized impairment loss"
A reversal of an impairment is a bookkeeping entry that reduces or eliminates a previously recorded write-down of an asset when evidence shows the asset’s recoverable amount has risen since the impairment was recognized. Accounting standards set specific limits: under IFRS an impairment loss for most non‑financial assets (but not goodwill) can be reversed up to the amount the asset would have had without the earlier impairment, while US GAAP generally prohibits reversing impairment losses for long‑lived assets held for use (though other narrow categories and different rules may apply), so whether and how an impairment reversal is allowed depends on the applicable accounting standard.
preliminary economic assessment technical
"completing its preliminary economic assessment"
A preliminary economic assessment is an initial analysis that estimates the potential profitability and feasibility of a project or resource, such as a new mineral deposit or development venture. It provides a rough idea of costs, benefits, and risks, helping investors decide whether to pursue more detailed studies. This early evaluation is important because it offers a snapshot of whether the project is worth further investment and development.
working capital financial
"working capital is calculated as current assets less current liabilities"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
non-IFRS measure financial
""Loss excluding impairment reversal" is net income (loss) less"
A non-IFRS measure is a financial number a company reports that is calculated outside standard accounting rules; it adjusts or removes items such as one-time costs, taxes, or accounting entries to highlight what management sees as the business’s recurring performance. Investors use these figures like a tailored snapshot to understand underlying trends — similar to a chef sharing a simplified recipe — but because they are not standardized, they require careful comparison and scrutiny.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash did Zentek (ZTEKF) have at September 30, 2026?

In Canadian dollars, Zentek had $13.6 million in cash and $11.3 million in working capital as of September 30, 2026. At March 31, 2026, it had $1.3 million in cash and a $1.3 million working-capital deficit. The May financing provided approximately $16 million in net proceeds.

Why did Zentek (ZTEKF) report quarterly net income of $17.2 million?

Zentek's quarterly net income included a $19.7 million non-cash impairment reversal for the Albany Graphite Project. Excluding that reversal, the company reported a $2.5 million loss, which it said was about the same as a year earlier.

What value did Zentek estimate for the Albany Graphite Project?

Management estimated the project's fair value less costs of disposal at approximately $45.5 million to $58.5 million, with a midpoint of approximately $52.0 million. The reversal was limited to approximately $19.7 million under the impairment-reversal carrying-value limit, leaving a carrying amount of approximately $28.8 million at September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-41310

ZENTEK LTD.
(Translation of registrant's name into English)

1123 York Road
Guelph, Ontario N1E 6Z1 Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐      Form 40-F ☒


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  ZENTEK LTD.
  (Registrant)
   
Date: November 17, 2026 By /s/ Wendy Ford
    Wendy Ford
    Chief Financial Officer


EXHIBIT INDEX

Exhibit   Description
   
99.1   News Release dated November 16, 2026 - Zentek Q2 Fiscal 2027 Results News Release



Zentek Q2 Fiscal 2027 Results News Release

Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash

Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026

Guelph, Ontario, November 16, 2026. Zentek Ltd. ("Zentek" or the "Company") (TSXV: ZEN) (OTCQX: ZTEKF) today reported results for the three and six months ended September 30, 2026, the second quarter of its 2027 fiscal year. The quarter reflects the Company's focus this year on putting its finances on a firm footing, so that it can fund the next steps for Albany and ZenGUARD™ from cash on hand.

The unaudited condensed interim consolidated financial statements and MD&A are available under the Company's profiles on SEDAR+ and EDGAR. All amounts are in Canadian dollars unless stated otherwise.

A stronger balance sheet

Balance sheet · September 30, 2026 vs. March 31, 2026

Strengthening the balance sheet was a priority this year. At March 31, 2026, Zentek had $1.3 million in cash and a working capital deficit of $1.3 million, which limited what the Company could commit to.

The May 2026 financing, which provided the Company with approximately $16 million in net proceeds, changed that. At September 30, 2026, cash was $13.6 million and working capital was $11.3 million. Total assets were $49.4 million, up from $15.1 million, mainly from the financing and the reversal of the previous impairment of the Albany Graphite Project (discussed below). Cash used in operating activities was $3.6 million for the six months, compared with $2.4 million a year earlier.

The Company put that capital to work. Since the financing closed, Zentek has spent $1.2 million on developing and de-risking the Albany Graphite Project, including completing its preliminary economic assessment ("PEA"). During the quarter, it also recruited new team members to build its commercial capability and its path to revenue.

During the period ended September 30, 2026, the Company assessed whether the impairment loss previously recognized on its Albany Graphite Project remained appropriate. In fiscal 2022, following a shift in the Company's business focus away from mining activities and toward healthcare solutions, the Company recognized an impairment charge of $19.7 million, reducing the carrying amount of the Albany Graphite Project from $26.7 million to $7.0 million. Following the Company's August 10, 2026 announcement of an updated PEA and mineral resource estimate, management concluded that the fair value less costs of disposal ("FVLCD") of the Albany Graphite Project was approximately $45.5 million to $58.5 million, with a midpoint of approximately $52.0 million.  Immediately before the impairment reversal, the carrying amount of the Albany Graphite Project was approximately $9.1 million. Although the estimated FVLCD exceeded the carrying amount, the reversal of a previously recognized impairment loss was limited to the carrying amount that would have been determined, net of amortization, had no impairment loss been recognized. Accordingly, the reversal recognized during the three and six months ended September 30, 2026 was limited to approximately $19.7 million, resulting in a carrying amount of approximately $28.8 million at September 30, 2026.


Net income for the quarter was $17.2 million, reflecting the $19.7 million non-cash Albany Graphite Project impairment reversal. Excluding it, the loss was $2.5 million, about the same as a year earlier (see "Non-IFRS measure" below).

Operating expenses rose 7% from a year earlier, mainly from higher professional fees, most of which were one-time costs, consulting fees, share-based compensation and listing fees, partly offset by salaries and benefits, which fell to $0.5 million from $1.0 million.

CEO quote

"2026 has been a year of putting fundamentals in place, and the last quarter was critical to that work. Our science is the foundation of this company. Turning it into a strong Canadian business also takes a defined path for each asset and the balance sheet to fund the next steps. That is where our attention has been this year. We deploy capital with discipline, stay focused on what moves each asset forward and keep the balance sheet efficient, because that is how lasting value is built. We built on the science and the assets this company has assembled over many years, and focused on the work that turns them into businesses: a completed preliminary economic assessment for Albany, ZenGUARD™ filters now selling in Canada and the United States, mask production under our own control, and $13.6 million in cash.

From here, our work is to keep reducing risk and building value, one documented step at a time: filling orders, showing our purification results hold at larger scale, and getting independent test results on our newer materials. We are in this for the mission. That means creating lasting value for our shareholders, for Constance Lake First Nation, our partner at Albany, for our team members, and for Canada. "

Mohammed Jiwan, CEO,  Zentek Ltd.

About Zentek

Zentek is an intellectual property development and commercialization company in advanced materials. It is focused on three platforms: specialty materials, including the ZenGUARD™ coating for filters and personal protective equipment; the Albany Graphite Project; and aptamer-based technologies held through its subsidiary, Triera Biosciences Ltd.

The Albany Graphite Project in Northern Ontario is 100% owned by Zentek through Albany Graphite Corp. It hosts igneous-hosted, fluid-derived natural graphite in a gabbro intrusion and breccia pipe vent system.


Non-IFRS measure

"Loss excluding impairment reversal" is net income (loss) less the impairment reversal of exploration and evaluation assets. It has no standardized meaning under IFRS and may not be comparable to similar measures of other issuers. Management uses it to show results from operations without a non-cash, non-recurring item. Reconciliation for the three months ended September 30, 2026: net income of $17,200,847 less the impairment reversal of $19,671,935 equals a loss of $2,471,088. For the six months: net income of $15,157,172 less $19,671,935 equals a loss of $4,514,763. No reversal was recorded in the comparative periods. "Working capital" also has no standardized meaning under IFRS and is calculated as current assets less current liabilities.

Forward-looking statements

This news release contains forward-looking statements, including statements about filling and growing ZenGUARD™ orders, the results and timing of purification, the use of proceeds, and the Albany Graphite Project and its PEA. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks described under "Risks and Uncertainties" in the Company's MD&A for the period ended September 30, 2026. Bench-scale and preclinical results are not necessarily indicative of results at larger scale or in clinical use. Zentek does not undertake to update forward-looking statements except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Mohammed (Moe) Jiwan, CEO

Mjiwan2@zentek.com , 437 567 6146


Filing Exhibits & Attachments

1 document

Keep reading